A multicenter, single blind Phase I/IIa study of IFNalpha Kinoid in dermatomyositis.
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2017
Price : $35 *
At a glance
- Drugs Interferon alpha kinoid (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2017 Status changed from planning to recruiting.
- 31 Oct 2017 New trial record
- 27 Oct 2017 According to a Neovacs media release, the company obtained U.S. FDA's acceptance of IND to expand this study into US. The study currently recruiting in European countries.